Greater angiogenic and immunoregulatory potency of bFGF and 5-aza-2'-deoxycytidine pre-treated menstrual blood stem cells in compare to bone marrow stem cells in rat model of myocardial infarction.
5-Azacytidine
Basic fibroblast growth factor
Bone marrow stem cells
Menstrual blood stem cells
Myocardial infarction
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
31 12 2022
31 12 2022
Historique:
received:
12
06
2022
accepted:
26
12
2022
entrez:
31
12
2022
pubmed:
1
1
2023
medline:
4
1
2023
Statut:
epublish
Résumé
This study is designed to compare the menstrual blood stem cells (MenSCs) and bone marrow stem cells (BMSCs)-secreted factors with or without pre-treatment regimen using basic fibroblast growth factor (bFGF) and 5-aza-2'-deoxycytidine (5-aza) and also regenerative capacity of pre-treated MenSCs and/or BMSCs in a rat model of myocardial infarction (MI). BMSCs and MenSCs were pre-treated with bFGF and 5-aza for 48 h and we compared the paracrine activity by western blotting. Furthermore, MI model was created and the animals were divided into sham, MI, pre-treated BMSCs, and pre-treated MenSCs groups. The stem cells were administrated via tail vain. 35 days post-MI, serum and tissue were harvested for further investigations. Following pre-treatment, vascular endothelium growth factor, hypoxia-inducible factor-1, stromal cell-derived factor-1, and hepatocyte growth factor were significantly increased in secretome of MenSCs in compared to BMSCs. Moreover, systemic administration of pre-treated MenSCs, leaded to improvement of cardiac function, preservation of myocardium from further subsequent injuries, promotion the angiogenesis, and reduction the level of NF-κB expression in compared to the pre-treated BMSCs. Also, pre-treated MenSCs administration significantly decreased the serum level of Interleukin 1 beta (IL-1β) in compared to the pre-treated BMSCs and MI groups. bFGF and 5-aza pre-treated MenSCs offer superior cardioprotection compare to bFGF and 5-aza pre-treated BMSCs following MI.
Sections du résumé
BACKGROUND
This study is designed to compare the menstrual blood stem cells (MenSCs) and bone marrow stem cells (BMSCs)-secreted factors with or without pre-treatment regimen using basic fibroblast growth factor (bFGF) and 5-aza-2'-deoxycytidine (5-aza) and also regenerative capacity of pre-treated MenSCs and/or BMSCs in a rat model of myocardial infarction (MI).
METHODS
BMSCs and MenSCs were pre-treated with bFGF and 5-aza for 48 h and we compared the paracrine activity by western blotting. Furthermore, MI model was created and the animals were divided into sham, MI, pre-treated BMSCs, and pre-treated MenSCs groups. The stem cells were administrated via tail vain. 35 days post-MI, serum and tissue were harvested for further investigations.
RESULTS
Following pre-treatment, vascular endothelium growth factor, hypoxia-inducible factor-1, stromal cell-derived factor-1, and hepatocyte growth factor were significantly increased in secretome of MenSCs in compared to BMSCs. Moreover, systemic administration of pre-treated MenSCs, leaded to improvement of cardiac function, preservation of myocardium from further subsequent injuries, promotion the angiogenesis, and reduction the level of NF-κB expression in compared to the pre-treated BMSCs. Also, pre-treated MenSCs administration significantly decreased the serum level of Interleukin 1 beta (IL-1β) in compared to the pre-treated BMSCs and MI groups.
CONCLUSIONS
bFGF and 5-aza pre-treated MenSCs offer superior cardioprotection compare to bFGF and 5-aza pre-treated BMSCs following MI.
Identifiants
pubmed: 36587199
doi: 10.1186/s12872-022-03032-7
pii: 10.1186/s12872-022-03032-7
pmc: PMC9805241
doi:
Substances chimiques
Decitabine
776B62CQ27
Fibroblast Growth Factor 2
103107-01-3
Azacitidine
M801H13NRU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
578Subventions
Organisme : Iran University of Medical Sciences
ID : 99-2-4-17061
Informations de copyright
© 2022. The Author(s).
Références
Stem Cell Res Ther. 2017 Nov 2;8(1):242
pubmed: 29096705
Mol Biol Rep. 2017 Feb;44(1):169-182
pubmed: 27981446
Stem Cell Res Ther. 2020 Feb 18;11(1):68
pubmed: 32070425
Mol Biotechnol. 2014 Dec;56(12):1151-62
pubmed: 25189461
Sci Rep. 2019 Jul 10;9(1):10007
pubmed: 31292483
Cardiovasc Res. 2012 Jun 1;94(3):400-7
pubmed: 22451511
J Cell Biochem. 2016 Aug;117(8):1934-46
pubmed: 26756870
Cardiovasc Res. 2011 Jan 1;89(1):129-38
pubmed: 20797985
Cureus. 2020 Jul 23;12(7):e9349
pubmed: 32742886
Tissue Eng Part A. 2012 Aug;18(15-16):1720-8
pubmed: 22571521
J Vis Exp. 2011 Feb 16;(48):
pubmed: 21372786
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
PLoS One. 2014 Feb 05;9(2):e86075
pubmed: 24505254
Cell Death Dis. 2020 May 11;11(5):349
pubmed: 32393744
PLoS One. 2012;7(11):e50924
pubmed: 23209838
Bioengineering (Basel). 2018 Apr 06;5(2):
pubmed: 29642402
Stem Cell Res Ther. 2018 May 11;9(1):129
pubmed: 29751831
Cell Stem Cell. 2012 Mar 2;10(3):244-58
pubmed: 22385653
J Thorac Cardiovasc Surg. 2006 Apr;131(4):889-97
pubmed: 16580449
Stem Cell Res Ther. 2019 Jul 8;10(1):204
pubmed: 31286993
Stem Cell Res Ther. 2015 Mar 17;6:32
pubmed: 25889741
Int J Oncol. 2013 Feb;42(2):535-42
pubmed: 23233163
Cell Death Dis. 2018 Feb 7;9(2):172
pubmed: 29416039
Cardiovasc Res. 2004 Apr 1;62(1):34-42
pubmed: 15023550
Mol Med Rep. 2018 Feb;17(2):2349-2356
pubmed: 29207135
Circ Res. 2016 Jan 8;118(1):95-107
pubmed: 26837742
Stem Cell Res Ther. 2019 Jun 3;10(1):158
pubmed: 31159859
Stem Cells Dev. 2007 Feb;16(1):31-7
pubmed: 17348804
Oxid Med Cell Longev. 2017;2017:3920195
pubmed: 28751931
Biologicals. 2019 Mar;58:64-72
pubmed: 30824230
J Cell Mol Med. 2018 Mar;22(3):1627-1639
pubmed: 29278305
Sci Rep. 2015 Jan 26;5:8020
pubmed: 25620445
Cell Transplant. 2008;17(3):303-11
pubmed: 18522233
Stem Cells Cloning. 2020 Nov 09;13:91-101
pubmed: 33204112
Stem Cells Transl Med. 2016 Sep;5(9):1127-32
pubmed: 27245365
Heart Lung Circ. 2017 Jul;26(7):648-659
pubmed: 28190758
Cytokine Growth Factor Rev. 2019 Apr;46:1-9
pubmed: 30954374
Int J Mol Sci. 2020 Oct 02;21(19):
pubmed: 33023264
Pharmacol Ther. 1985;28(1):17-27
pubmed: 2414786
Cancer Sci. 2018 Mar;109(3):560-571
pubmed: 29285833
PLoS One. 2017 Jun 29;12(6):e0179972
pubmed: 28662151